Abstract Number: 2206 • ACR Convergence 2023
Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis
Background/Purpose: MAIT (mucosal associated invariant T) cells are involved in mucosa defense against bacteria. This cellular subset is characterized by a semi-invariant αβ TCR and…Abstract Number: 2224 • ACR Convergence 2023
Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes
Background/Purpose: The term "Difficult-to-Treat" (D2T) defines those patients who remain active despite having undergone various treatments within the established recommendations. This concept is defined by…Abstract Number: 0370 • ACR Convergence 2023
Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in children with juvenile spondyloarthritis (JSpA) and generally represent the first-line choice for biologic therapy. However, not…Abstract Number: 0523 • ACR Convergence 2023
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic rheumatic disease which requires optimal management and disease control. Patients (pts) can experience loss of response in the…Abstract Number: 0841 • ACR Convergence 2023
Spondyloarthritis Research and Treatment Network (SPARTAN) Draft Referral Recommendations for Axial Spondyloarthritis
Background/Purpose: In the United States (US), the diagnosis of axial spondyloarthritis (axSpA) continues to be delayed by an average of 10 years from symptom onset.…Abstract Number: 1391 • ACR Convergence 2023
Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care
Background/Purpose: Achieving remission is the treatment target for patients (pts.) with axial spondyloarthritis (axSpA).Remission rates over longer periods in a real-life setting have not been…Abstract Number: 1644 • ACR Convergence 2023
The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Spondyloarthritis Patients
Background/Purpose: Nearly 8% of patients with spondyloarthritis (SpA) manifest symptoms that are compatible with active inflammatory bowel disease (IBD), despite not having any previous diagnosis…Abstract Number: 1886 • ACR Convergence 2023
Costotransverse Joint Ankylosis and Association with Syndesmophyte Progression in Patients with Radiographic Axial Spondyloarthritis
Background/Purpose: Costotransverse joint ankylosis in radiographic axial spondyloarthritis (r-axSpA) patients was measured. Furthermore, the association between syndesmophyte progression assessed by CT syndesmophyte score (CTSS) and…Abstract Number: 2207 • ACR Convergence 2023
Knowledge, Awareness, and Attitudes Regarding Inflammatory Back Pain Among Non-Rheumatology Physicians in the United States
Background/Purpose: Inflammatory back pain (IBP) is the defining feature of axial spondyloarthritis (axSpA). However, it may be difficult for non-rheumatology physicians (non-rheums) to distinguish between…Abstract Number: 2225 • ACR Convergence 2023
Long-term Evolution of Spondyloarthritis Patients Included in REGISPONSER, 17 Years Later (REGISPON-3 Study)
Background/Purpose: The cross-sectional REGISPONSER study was conducted in 2004 in 31 centers from Spain, including a total of 2367 patients who met the European Spondyloarthropathy…Abstract Number: 0372 • ACR Convergence 2023
Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial
Background/Purpose: Secukinumab has demonstrated efficacy and safety in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) categories of juvenile idiopathic arthritis (JIA) for…Abstract Number: 0524 • ACR Convergence 2023
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting more than a third of patients. However, long-term interventional…Abstract Number: 0842 • ACR Convergence 2023
Low Rate of Switching from Nr-axSpA to r-axSpA After 10 Years of Follow up in Early Axialspondyloarthritis. Data from DESIR Cohort
Background/Purpose: The objective of this analysis was to evaluate the proportion of patients switching from non-radiographic axSpA (nr-axSpA) toradiographic axSpA (r-axSpA) after 10 years of…Abstract Number: 1392 • ACR Convergence 2023
Improving the Diagnostic Accuracy in Axial Spondyloarthritis: Interim Results of a Nationwide Telemedicine Project
Background/Purpose: Axial spondyloarthritis (axSpA) is often diagnosed late, while there is also a problem of over- and misdiagnosis in patients with chronic back pain. Imaging,…Abstract Number: 1776 • ACR Convergence 2023
Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease with multifactorial origins, primarily affecting the musculoskeletal system. Gut inflammation is seen in the majority of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 33
- Next Page »